Document:

EX-10.6

 Exhibit 10.6 
  

 
 October 21, 2016 

Eleanor L. Ramos, M.D. 
 Re: Separation from Employment

 Dear Leni: 
 This letter confirms our agreement concerning
your departure from Global Blood Therapeutics, Inc. (the “Company”). Your last day of employment with the Company will be October 24, 2016 (the “Separation Date”). 

Regardless of whether you enter into this Agreement, you will receive your final paycheck, which includes your final pay and any accrued, but unused, vacation
time through the Separation Date. Any outstanding business expenses should be submitted within ten (10) days of your last day of employment, along with receipts or other supporting documentation of each expense. 

Severance 
 Although it is under no legal obligation to do
so, provided you enter into, do not revoke and comply with this Agreement, the Company agrees to pay you a separation benefit in the amount of $190,000.00, less all applicable withholdings, which is equal to six (6) months pro rata portion
of your current base salary. You will receive your separation benefit within ten (10) business days after the Effective Date of this Agreement (as defined below). 

You will be eligible to convert your medical insurance coverage under COBRA and will receive information from our plan administrator describing this
conversion election. Your health coverage through the Company’s health plan will remain in force through October 31, 2016. In further consideration of your general release of claims, if you enroll in and remain eligible for COBRA, the
Company will cover the Company’s portion of your COBRA premiums from November 1, 2016 through April 30, 2017. Except for the separation terms proposed in this letter, you will not be entitled to any compensation, equity, benefits or other
perquisites of employment after the Separation Date. 
 The Company also confirms that if you choose to file for unemployment benefits with the State of
California, that the Company will take no action to deny you said benefits. 
 Equity 

You agree that the following table sets forth the only interest, equity or otherwise, you own in the Company, and that all the grants are subject to the Global
Blood Therapeutics 2015 Stock Option and Incentive Plan and the applicable Stock Option Agreements (each a “Stock Option Agreement”) (collectively, the “Equity Documents”): 

 
  

400 East Jamie Court  ●  Suite 101  ●  South San Francisco, CA
94080    t (650) 741-7700    f (650) 741-7701 
 www.globalbloodtx.com 

  

 

 
  

											
	 Type of Grant
	  	Number of
Shares	  	 Date of Grant
	  	Vested
Shares as of
Separation
Date	 	  	Shares to be
Accelerated,
Subject to you
Entering into and
Complying with
this Agreement
	 Stock Option (time-based vesting)
	  	142,857	  	June 11, 2014	  	 	80,357	 	  	54,999
	 Stock Option (performance-based vesting)
	  	37,142	  	April 9, 2015	  	 	18,572	 	  	0
	 Stock Option (time-based vesting)
	  	77,142	  	April 9, 2015	  	 	28,928	 	  	0

 Acceleration 
 Although it
is under no legal obligation to do so, provided you enter into and comply with this Agreement, the Company shall accelerate your vesting as of the Separation Date with respect to an aggregate of 54,999 Shares (representing the aggregate number of
Shares that would have vested under all of your time-based equity grants had you remained employed with the Company through October 24, 2017) comprised of 54,999 Shares under your Option Agreement for the grant dated June 11, 2014. If you
do not enter into and comply with this Agreement, the vesting of all of your equity grants will cease on the Separation Date and no acceleration will apply. In either event, the grants will continue to be governed by the Equity Documents. You also
acknowledge and agree the vesting of all of your equity grants will cease on the Separation Date, and you will not be entitled to any additional vesting or acceleration other than as specifically described above. 

Stock Option Exercise Rights 
 Pursuant to the terms of
the Stock Option Agreements, whether or not you enter into this Agreement, (a) with respect to the June 11, 2014 Stock Option (time-based vesting), you may exercise (to the extent not previously exercised) all option shares as listed above
as “Vested Shares as of Separation Date,” to the extent not previously exercised, (b) with respect to the April 9, 2015 Stock Option Agreement (time-based vesting), all option shares listed above as “Vested Shares as of the
Separation Date” shall be exercisable; and (c) with respect to the April 9, 2015 Stock Option Agreement (with performance-based vesting) all option shares listed above as “Vested as of the Separation Date” shall be exercisable.
If you enter into and comply with this Agreement, you may also exercise all option shares as listed above as “Shares to be Accelerated, Subject to you Entering into and Complying with this Agreement.” In any event, you must exercise your
right with respect to Vested Shares within 90 days of the Separation Date consistent with the terms of the Equity Documents. 
 Release 

In exchange for, among other things, the foregoing separation benefit and benefit continuation and accelerated vesting, you completely release and forever
discharge Global Blood Therapeutics, Inc., its affiliated, related, parent or subsidiary entities, and its and their present and former directors, officers, and employees (the 

 
  

  
 400 East Jamie
Court  ●  Suite 101  ●  South San Francisco, CA 94080    t (650) 741-7700    f (650) 741-7701 

www.globalbloodtx.com 

 

 
 “Released Parties”) from any and all claims you may now have or have ever had against any of them through the
date you sign this Agreement including, but not limited to, any claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Age Discrimination in Employment Act of
1967 (“ADEA’’) the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Employee Retirement Income
Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act of 2002; the Immigration Control and Reform Act; the California Family Rights Act; the California Labor Code; and
the California Fair Employment and Housing Act or any other claims for violation of any federal, state, or municipal statutes, and any and all claims for attorneys’ fees and costs (the “Released Claims”). The parties intend for this
release to be enforced to the fullest extent permitted by law. You understand that you are not waiving any right or claim that cannot be waived as a matter of law, such as workers’ compensation or unemployment insurance benefits. You agree not
to file or initiate any lawsuit concerning the Released Claims. You understand that this release does not prevent you from filing a charge with or participating in an investigation by a governmental administrative agency; provided, however, that you
hereby waive any right to receive any monetary award resulting from such a charge or investigation. 
 You acknowledge that you have been advised by the
Company to consult with legal counsel prior to entering into this Agreement. You further acknowledge that you are familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown
claims, which provides as follows: 
  

					
		 	A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER
SETTLEMENT WITH THE DEBTOR.	 	

 Being aware of said code section, you agree to expressly waive any rights you may have thereunder, as well as under any other
statute or common law principles of similar effect. 
 You acknowledge that the separation payment and benefits described above exceed the amount to which
you otherwise are entitled. 
 Continuing Obligations 

Please remember that even after your employment with the Company ends, you must comply with your continuing obligation to maintain the confidentiality of the
Company’s proprietary information, including your obligations under the Employee Confidentiality and Assignment Agreement you signed on March 8, 2014 as a condition of your employment (the “Confidential Information Agreement”).
Notwithstanding the return of property provisions in the Confidential Information Agreement, you may retain possession of the Company issued laptop computer that is currently in your possession on the condition that you delete and finally purge all
information from the laptop by wiping it clean. By signing below you represent that you have, in fact, wiped the laptop clean. 
 You further agree not to
make or publish, either orally or in writing, any disparaging statement about the Released Parties and the Company agrees to instruct its senior management team not to make or publish, either 

 
  

  
 400 East Jamie
Court  ●  Suite 101  ●  South San Francisco, CA 94080    t (650) 741-7700    f (650) 741-7701 

www.globalbloodtx.com 

 

 
  

 
orally or in writing, any disparaging statement about you. You understand that nothing contained in this Agreement limits your ability to file a charge or complaint with the Equal Employment
Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government
Agencies”). You further understand that this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including
providing documents or other information, without notice to the Company. This Agreement does not limit your right to receive an award for information provided to any Government Agencies. 

Entire Agreement: Consideration Period. 
 This letter,
which may be subject to disclosure by the Company as required by law or for legitimate business reasons, contains all of our agreements and understandings and fully supersedes any prior agreements or understandings that we may have had regarding
your employment with the Company or the termination of your employment, with the exception of the Confidential Information Agreement and the Equity Documents. This agreement is governed by California law and may be amended only in a written document
signed by both of us. If any term in this agreement is unenforceable, the remainder of the agreement will remain enforceable. 
 Please note that you have
until November 11, 2016 to consider this Agreement (but you may sign it earlier if you so desire). You acknowledge and agree that this provides you with more than a twenty-one (21) day consideration period. In addition, you have a right to
revoke this Agreement within seven (7) days of signing it by sending me a written notice to that effect. This agreement shall not become effective or enforceable and the separation benefit will not be provided until the next business day after
the seven-day revocation period has expired (the “Effective Date”). 
 Please contact me if you have any questions. We wish you the best in your
future endeavors. 
 Very truly yours, 
  

	
	 /s/ Matt Krause

	Matt Krause
	Senior Director, Human Resources

 ACCEPTED AND AGREED: 
  

											
	Dated:	 	7 November 2016	 		 	Signature:	 	 /s/ Eleanor L. Ramos, M.D.
	 	
		 		 		 		 	Eleanor L. Ramos, M.D.	 	
		 		 		 		 		 	
		 		 		 		 		 	

  
  

  
 400 East Jamie
Court  ●  Suite 101  ●  South San Francisco, CA 94080    t (650) 741-7700    f (650) 741-7701 

www.globalbloodtx.comEX-10.17

 Exhibit 10.17 
  

 
 GLOBAL BLOOD THERAPEUTICS, INC. 

400 EAST JAMIE COURT, SUITE 101 

SOUTH SAN FRANCISCO, CA 94080 
 October 7,
2016 
 Patricia Suvari, JD 
 Dear Tricia, 

Global Blood Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 

1. Position. Your initial title will be Chief Legal Officer, and you will initially report to Ted Love. This is a full-time position. While you render
services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to
the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 
 2.
Cash Compensation. The Company will pay you a starting salary at the rate of $365,000 per year, payable in accordance with the Company’s standard payroll schedule. This salary will be subject to adjustment pursuant to the Company’s
employee compensation policies in effect from time to time. In addition to your salary, you will be eligible to participate in the Annual Performance-Based Cash Incentive Award Program which is based on the achievement of Company performance goals
and your personal goals to be set with your manager. Your initial bonus target will be 40% of your annual base salary. Please note your start date occurs in the fourth quarter of 2016, therefore your first bonus will be for the performance year
2017. 
 3. Employee Benefits. As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits.
Should you decide to participate in the Company health benefits program, your coverage will begin the first day of the month following your start date. In addition, you will be entitled to 20 days of paid time off in accordance with the
Company’s policy. 
 4. Stock Options. Subject to the approval of the Company’s Board of Directors or its Compensation Committee, you will
be granted an option to purchase 100,000 shares of the Company’s Common Stock. The exercise price per share will be determined by the Board of Directors or the Compensation Committee when the option is granted. The option will be subject to the
terms and conditions applicable to options granted under the Company’s 2015 Stock Plan (the “Plan”), as described in the Plan and the applicable stock option agreement. You will vest in 25% of the option shares after 12 months of
continuous service, and the balance will vest in equal quarterly installments over the next 36 months of continuous service, as described in the applicable stock option agreement. 

5. Change in Control. You will be eligible to participate in the Company’s Change in Control Policy. In accordance with the policy’s terms,
which the Company retains the right to amend, revise, change or end at any time, if your employment is terminated without Cause (as defined in the Plan) within one year after the closing of a Sale Event (as defined in the Plan), you will receive
certain benefits provided that you first execute and not revoke a severance agreement including a general release of claims. Currently those benefits are: (a) full acceleration of vesting of your outstanding equity awards under the Plan (as set
forth in the Plan); (b) a lump sum equal to nine months of your base salary; (c) a lump sum equal to your then-current target bonus; and (d) if you are participating in the Company group health plan immediately prior to termination
and you elect COBRA, a monthly cash payment for 9 months equal to the Company’s monthly premium contribution. This section is not intended to modify the Change in Control Policy and is provided merely as an introductory summary of the
policy’s current terms. A copy of the Change in Control Policy will be available from Human Resources upon request after your start date. 

 6. Employee Confidentiality and Assignment Agreement. Like all Company employees, you will be required, as
a condition of your employment with the Company, to sign the Company’s standard Employee Confidentiality and Assignment Agreement, a copy of which is attached hereto as Exhibit A. 

7. Background Check. The Company may conduct a background or reference check (or both). If so, then you agree to cooperate fully in tnose procedures,
and this offer is subject to the Company’s approving the outcome of those checks, in the discretion of the Company. 
 8. Employment Relationship.
Employment with the Company is for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without
cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, reporting relationship,
compensation and benefits, as well as the Company’s personnel policies·and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and
a duly authorized officer of the Company (other than you). 
 9. Taxes. All forms of compensation referred to in this letter agreement are subject to
reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not
make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation. 
 10. Interpretation, Amendment
and Enforcement. This letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or
understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of
this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company
or any other relationship between you and the Company will be governed by California law, excluding laws relating to conflicts or choice of law. 

* * * * * 
 We hope that you will
accept our offer to join the·company. You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and
Inventions Agreement and returning them to me. This offer, if not accepted, will expire at the close of business on October 10, 2016. As required by law, your employment with the Company is contingent upon your providing legal proof of your
identity and authorization to work in the United States. Your employment is also contingent upon your starting work with the Company on October 11, 2016. 

If you have any questions, please call me at 650.741.7746. 

 

	
	Very truly yours,
	
	 /s/ Matt Krause

	Matt Krause
	 Senior Director, Human Resources

GLOBAL BLOOD THERAPEUTICS, INC.

 I have read and accept this employment offer: 
  

	
	 /s/ Patricia Suvari, JD

	Patricia Suvari, JD

 Dated: Oct, 7, 2016 

Attachment 
 Exhibit A: Employee Confidentiality and
Assignment Agreement 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]